Benzinga's Top #PreMarket Gainers

shares jumped 24.46% to $28.44 in pre-market trading following Sunday announcement that solithromycin met primary and secondary objectives of non-inferiority compared to moxifloxacin in the treatment of CABP.

shares jumped 17.70% to $9.51 in pre-market trading. Conatus will report top-line results from ACLF and organ impairment clinical trials of emricasan on January 8, 2015.

shares rose 4.98% to $8.01 in pre-market trading after the company declared common and preferred unit distributions, and issued preliminary operating information for 2014 and full year 2015 forecast. The company expected 2015 EBITDA of $650 to $700 million and capex of $200 million.

shares gained 4.89% to $21.25 in the pre-market trading session. Baird upgraded El Pollo Loco from Neutral to Outperform.

shares surged 4.45% to $6.80 in pre-market trading after the company reported that its EU Phase 3 trial of INTERCEPT red blood cells has met the primary endpoint.